Company / Free Cash Flow
NewAmsterdam Pharma Co N.V. Free Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$148.0M
FY2025
5-year range
-$159.2M / $10.4M
FY2021-FY2025
Trend
+7.0%
vs FY2024
Sector context
#133 of 195
Health Care
What the data says
At -$148M, NewAmsterdam Pharma Co N.V.'s free cash flow ranks #133 of 195 in the Health Care sector. Free Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$148M.
Based on SEC 10-K filings.
-$148M in FY2025.
Declined from -$141M to -$148M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#133 of 195 in Health CareTop 68% of 195This company -$148.0M Sector average $465.6M
▼
-131.8% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 7.0% year-over-year.
- Ranks #133 out of 195 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$148.0M | +7.0% |
| FY2024 | -$159.2M | -12.7% |
| FY2023 | -$141.2M | -1452.4% |
| FY2022 | $10.4M | +135.4% |
| FY2021 | -$29.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026